Payment overview · 2025
General Payments
$3,310.82
181 reported records · 24 companies
Healthcare provider profile · identity verified
Jane Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND BLANC, MI · NPI 1427132877
Verified facts
What the public records show
CMS Open Payments records show Jane Johnson, M.D. received $3,310.82 in general payments during 2025 across 181 reported records.
ABBVIE INC. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $466.63 | 14.1% | 34 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $298.32 | 9.0% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $276.27 | 8.3% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $214.71 | 6.5% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.69 | 6.5% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $199.98 | 6.0% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $183.87 | 5.5% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $173.58 | 5.2% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $163.21 | 4.9% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $150.33 | 4.5% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.10 | 4.4% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $103.33 | 3.1% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $102.57 | 3.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.75 | 3.0% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $96.83 | 2.9% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $74.78 | 2.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.88 | 2.1% | 3 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $65.83 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.87 | 1.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.88 | 1.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.71 | 1.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.32 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.52 | 0.6% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $13.86 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,310.82 | 181 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $298.32 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $266.09 | 14 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $214.71 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $205.90 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $183.87 | 11 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $173.58 | 9 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $163.21 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $162.19 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $160.01 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $153.17 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.40 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $133.75 | 8 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $133.22 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $132.34 | 6 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $124.53 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.02 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.02 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $105.46 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $105.46 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.27 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.81 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $86.57 | 4 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $76.09 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $74.78 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $74.36 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $70.88 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.87 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $48.88 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.71 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $39.64 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.11 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $10.18 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $10.18 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $10.18 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 192 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
192 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 26 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 528 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 117 |
| Gabapentin | Gabapentin | 304 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 92 |
| Omeprazole | Omeprazole | 297 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 100 |
| Losartan Potassium | Losartan Potassium | 225 | 74 |
| Montelukast Sodium | Montelukast Sodium | 221 | 71 |
| Lisinopril | Lisinopril | 214 | 65 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 192 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 55 |
| Simvastatin | Simvastatin | 185 | 59 |
| Famotidine | Famotidine | 179 | 62 |
| Pregabalin | Pregabalin | 179 | 49 |
| Eliquis | Apixaban | 163 | 42 |
| Jardiance | Empagliflozin | 163 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 51 |
| Prednisone | Prednisone | 155 | 100 |
| Ibuprofen | Ibuprofen | 153 | 43 |
| Tramadol Hcl | Tramadol Hcl | 151 | 47 |
| Trazodone Hcl | Trazodone Hcl | 124 | 37 |
| Alendronate Sodium | Alendronate Sodium | 111 | 39 |
| Alprazolam | Alprazolam | 105 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 32 |
| Metformin Hcl | Metformin Hcl | 98 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 28 |
| Furosemide | Furosemide | 93 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 31 |
| Buspirone Hcl | Buspirone Hcl | 90 | 25 |
| Meloxicam | Meloxicam | 88 | 33 |
| Ventolin Hfa | Albuterol Sulfate | 87 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 29 |
| Fluconazole | Fluconazole | 82 | 44 |
| Farxiga | Dapagliflozin Propanediol | 80 | 28 |
| Glimepiride | Glimepiride | 80 | 28 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 79 | 28 |
| Sertraline Hcl | Sertraline Hcl | 78 | 21 |
| Trulicity | Dulaglutide | 75 | 26 |
| Carvedilol | Carvedilol | 69 | 25 |
| Levofloxacin | Levofloxacin | 68 | 54 |
| Cephalexin | Cephalexin | 67 | 51 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 24 |
| Nystatin | Nystatin | 64 | 37 |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 20 |
| Metformin Hcl Er | Metformin Hcl | 63 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 17 |
| Baclofen | Baclofen | 61 | 15 |
| Potassium Chloride | Potassium Chloride | 60 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 34 |
| Mounjaro | Tirzepatide | 57 | 17 |
| Allopurinol | Allopurinol | 54 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 19 |
| Buprenorphine | Buprenorphine | 53 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 31 |
| Spironolactone | Spironolactone | 49 | 21 |
| Azithromycin | Azithromycin | 48 | 40 |
| Xarelto | Rivaroxaban | 48 | 13 |
| Atenolol | Atenolol | 47 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Ozempic | Semaglutide | 47 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Clonidine Hcl | Clonidine Hcl | 40 | 15 |
| Januvia | Sitagliptin Phosphate | 40 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 21 |
| Entresto | Sacubitril/Valsartan | 38 | 11 |
| Acyclovir | Acyclovir | 37 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 14 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Topiramate | Topiramate | 34 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 12 |
| Methocarbamol | Methocarbamol | 32 | 12 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 15 |
| Promethazine Hcl | Promethazine Hcl | 31 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | 21 |
| Linzess | Linaclotide | 29 | 13 |
| Naproxen | Naproxen | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 18 |
| Amoxicillin | Amoxicillin | 24 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | 11 |
| Cefdinir | Cefdinir | 21 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 12 |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,310.82 · 181 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GIMOTI, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, RINVOQ, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VIVITROL, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error